LYC-55716 + pembrolizumab

LYC-55716 + pembrolizumab is a combination therapy under clinical investigation for advanced solid tumors, including metastatic non-small cell lung cancer and other cancers. LYC-55716 (also known as cintirorgon) is a first-in-class, oral small-molecule agonist of the retinoic acid receptor–related orphan receptor gamma (RORγ), developed to enhance anti-tumor immune responses by reprogramming immune cells—specifically increasing effector T-cell activity and reducing immunosuppressive mechanisms. Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) on T cells, blocking an inhibitory pathway used by cancer cells to evade immune detection. The combination aims to synergistically boost anti-tumor immunity through complementary mechanisms of action. Clinical trials have focused on safety, tolerability, pharmacodynamics, and preliminary efficacy in patients with relapsed or refractory solid tumors[2][3][4][5].

Brand names

Keytruda

Other names

LYC-55716 + Keytruda